ABIOMED INC Quarterly Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest in USD from Q2 2014 to Q3 2022
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
-
Summary
-
Abiomed Inc quarterly/annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest history and growth rate from Q2 2014 to Q3 2022.
- Abiomed Inc Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending September 30, 2022 was $139M, a 106% increase year-over-year.
- Abiomed Inc Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the twelve months ending September 30, 2022 was $341M, a 60.8% increase year-over-year.
- Abiomed Inc annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2021 was $191M, a 33.9% decline from 2020.
- Abiomed Inc annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2020 was $288M, a 12.2% increase from 2019.
- Abiomed Inc annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2019 was $257M, a 2.48% decline from 2018.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Trailing 12 Months (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Quarterly (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Quarterly Growth (%)